368 related articles for article (PubMed ID: 9868989)
1. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
Owens DR
Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
[TBL] [Abstract][Full Text] [Related]
2. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?
Nattrass M; Lauritzen T
Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S21-31. PubMed ID: 11063281
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
4. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.
Culy CR; Jarvis B
Drugs; 2001; 61(11):1625-60. PubMed ID: 11577798
[TBL] [Abstract][Full Text] [Related]
5. A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes.
Moses R
Expert Opin Pharmacother; 2000 Dec; 1(7):1455-67. PubMed ID: 11249478
[TBL] [Abstract][Full Text] [Related]
6. Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with Type 2 diabetes.
Landgraf R; Frank M; Bauer C; Dieken ML
Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S38-44. PubMed ID: 11063283
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology and clinical experience with repaglinide.
Massi-Benedetti M; Damsbo P
Expert Opin Investig Drugs; 2000 Apr; 9(4):885-98. PubMed ID: 11060717
[TBL] [Abstract][Full Text] [Related]
8. Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes.
Van Gaal LF; Van Acker KL; De Leeuw IH
Diabetes Res Clin Pract; 2001 Sep; 53(3):141-8. PubMed ID: 11483229
[TBL] [Abstract][Full Text] [Related]
9. Repaglinide--a new compound for the treatment of patients with type 2 diabetes.
Wolffenbuttel BH
Neth J Med; 1999 Nov; 55(5):229-34. PubMed ID: 10593133
[TBL] [Abstract][Full Text] [Related]
10. Repaglinide: a new short-acting insulinotropic agent for the treatment of type 2 diabetes.
Owens DR
Eur J Clin Invest; 1999 Jun; 29 Suppl 2():30-7. PubMed ID: 10383608
[TBL] [Abstract][Full Text] [Related]
11. The importance of early insulin secretion and its impact on glycaemic regulation.
Garber AJ
Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S32-7. PubMed ID: 11063282
[TBL] [Abstract][Full Text] [Related]
12. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide.
Schmitz O; Lund S; Andersen PH; Jønler M; Pørksen N
Diabetes Care; 2002 Feb; 25(2):342-6. PubMed ID: 11815507
[TBL] [Abstract][Full Text] [Related]
13. Repaglinide: prandial glucose regulation in clinical practice.
Owens DR; McDougall A
Diabetes Obes Metab; 2000 Mar; 2 Suppl 1():S43-8. PubMed ID: 11225759
[TBL] [Abstract][Full Text] [Related]
14. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
[TBL] [Abstract][Full Text] [Related]
15. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.
Owens DR; Luzio SD; Ismail I; Bayer T
Diabetes Care; 2000 Apr; 23(4):518-23. PubMed ID: 10857945
[TBL] [Abstract][Full Text] [Related]
16. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.
Damsbo P; Clauson P; Marbury TC; Windfeld K
Diabetes Care; 1999 May; 22(5):789-94. PubMed ID: 10332683
[TBL] [Abstract][Full Text] [Related]
17. Repaglinide.
Balfour JA; Faulds D
Drugs Aging; 1998 Aug; 13(2):173-80. PubMed ID: 9739505
[TBL] [Abstract][Full Text] [Related]
18. Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes.
Damsbo P; Marbury TC; Hatorp V; Clauson P; Müller PG
Diabetes Res Clin Pract; 1999 Aug; 45(1):31-9. PubMed ID: 10499883
[TBL] [Abstract][Full Text] [Related]
19. Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide.
Owens DR; Cozma LS; Luzio SD
Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):19-27. PubMed ID: 12702004
[TBL] [Abstract][Full Text] [Related]
20. Repaglinide in combination therapy.
Moses R
Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):33-8. PubMed ID: 12702006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
